Company & Sponsor Intelligence
Otsuka Pharmaceutical Co., Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting0
Completed1
Countries1
Therapeutic footprint
unclassified
Indexed studies
NCT01634243A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
parkinsons · JapanPHASE2
parkinsons · JapanPHASE2
NCT00882362Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
unclassified · JapanPHASE3
unclassified · JapanPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →